Kickbacks, courtesies or cost-effectiveness?: Application of the Medicare antikickback Law to the marketing and promotional practices of drug and medical device manufacturers.
This article summarizes the purposes and history of the antikickback law and describes its evolution into a potent weapon against the corruption of medical decision making in the procurement of prescription drugs and medical devices. The article also details a variety of strategies for reducing risks under the law in several key areas of importance to manufacturers. While the purposes of the law are laudable, its current broad interpretation may impede not only corruption, but also benign forms of customer relations and innovative approaches to cost-effective medical care.
Bulleit
T N
TN
Hogan & Hartson, L.L.P., Washington, D.C., USA.
Krause
J H
JH
D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004864:Equipment and Supplies; D005607:Fraud / Q000331:legislation & jurisprudence / Q000517:prevention & control; D019981:Health Care Sector / Q000331:legislation & jurisprudence; D006801:Humans; D007221:Industry / Q000331:legislation & jurisprudence; D008389:Marketing of Health Services / Q000331:legislation & jurisprudence*; D006278:Medicare / Q000331:legislation & jurisprudence*; D012017:Referral and Consultation / Q000331:legislation & jurisprudence*; D012308:Risk Management; D014481:United States